Shinsuke Takagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shinsuke Takagi has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
Shuichi Taniguchi
Department of Hematology, Toranomon Hospital, Tokyo, Japan
14 shared publicationsHisashi Yamamoto
Department of Hematology, Toranomon Hospital, Tokyo, Japan
13 shared publicationsAtsushi Wake
Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan
12 shared publicationsAya Nishida
Department of Hematology, Toranomon Hospital, Tokyo, Japan
11 shared publicationsKazuya Ishiwata
Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan
11 shared publicationsYuki Asano-Mori
Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan
11 shared publications
Latest Publications
- 24 July 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (3) , 328-333
Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study
- 24 July 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (3) , 328-333
Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study
- 13 April 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (5) , 639-644
Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study
Late-onset sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation remains difficult to diagnose and treat. We retrospectively analyzed 14 umbilical cord blood transplant recipients who developed late-onset SOS and received defibrotide at Toranomon Hospital between 2019 and 2021. All patients presented with very severe SOS accompanied by multiorgan failure. The cumulative incidence of complete remission was 35.7% at one year after initiation of defibrotide therapy. Overall survival was 57.1% at day 100 and 35.7% at two years after SOS diagnosis. Patients with anicteric SOS tended to have better survival than those with icteric disease. Defibrotide was generally well tolerated, with only two grade ≥ 3 bleeding events. Despite the small sample size and retrospective design, these findings suggest that Defibrotide may provide clinical benefit in patients with late-onset SOS following umbilical cord blood transplantation.
- 13 April 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (5) , 639-644
Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study
Late-onset sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic cell transplantation remains difficult to diagnose and treat. We retrospectively analyzed 14 umbilical cord blood transplant recipients who developed late-onset SOS and received defibrotide at Toranomon Hospital between 2019 and 2021. All patients presented with very severe SOS accompanied by multiorgan failure. The cumulative incidence of complete remission was 35.7% at one year after initiation of defibrotide therapy. Overall survival was 57.1% at day 100 and 35.7% at two years after SOS diagnosis. Patients with anicteric SOS tended to have better survival than those with icteric disease. Defibrotide was generally well tolerated, with only two grade ≥ 3 bleeding events. Despite the small sample size and retrospective design, these findings suggest that Defibrotide may provide clinical benefit in patients with late-onset SOS following umbilical cord blood transplantation.
- Open Access
- 9 April 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (2)
Prognostic nutritional index and geriatric nutritional risk index in lisocabtagene maraleucel for B-cell lymphoma
- 9 April 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (2)
Open AccessPrognostic nutritional index and geriatric nutritional risk index in lisocabtagene maraleucel for B-cell lymphoma
- 5 February 2026
- Published by Springer Nature in Mycopathologia
- Vol. 191 (2) , 30
Fatal Ultra-Early-Onset Rhino-Cerebral Mucormycosis Caused by Rhizomucor miehei Following Umbilical Cord Blood Transplantation and Review of Published Literature
A 43-year-old man with myelodysplastic syndrome underwent umbilical cord blood transplantation (CBT). On day 4 post-transplantation, he developed right periorbital pain and oculomotor nerve palsy. Brain MRI revealed fluid accumulation in the sphenoid sinus and mucosal thickening in the right maxillary sinus. Given the extraordinarily early onset and neurological involvement, fungal meningitis, including mucormycosis, was suspected, and empirical high-dose liposomal amphotericin B (10 mg/kg/day) was initiated. Nasal discharge culture yielded Rhizomucor species, later identified as Rhizomucor miehei by polymerase chain reaction (PCR). Despite aggressive antifungal therapy, the patient's neurological condition deteriorated, and he died on day 49. Autopsy confirmed extensive rhino-cerebral mucormycosis with angioinvasion, and Mucorales DNA was detected in brain tissue by quantitative PCR. To our knowledge, this represents the first reported case of R. miehei infection occurring within days after transplantation, preceding neutrophil engraftment. This case highlights the importance of recognizing mucormycosis even in the immediate post-transplant period and underscores the limitations of antifungal therapy in the absence of surgical debridement.
- 5 February 2026
- Published by Springer Nature in Mycopathologia
- Vol. 191 (2) , 30
Fatal Ultra-Early-Onset Rhino-Cerebral Mucormycosis Caused by Rhizomucor miehei Following Umbilical Cord Blood Transplantation and Review of Published Literature
A 43-year-old man with myelodysplastic syndrome underwent umbilical cord blood transplantation (CBT). On day 4 post-transplantation, he developed right periorbital pain and oculomotor nerve palsy. Brain MRI revealed fluid accumulation in the sphenoid sinus and mucosal thickening in the right maxillary sinus. Given the extraordinarily early onset and neurological involvement, fungal meningitis, including mucormycosis, was suspected, and empirical high-dose liposomal amphotericin B (10 mg/kg/day) was initiated. Nasal discharge culture yielded Rhizomucor species, later identified as Rhizomucor miehei by polymerase chain reaction (PCR). Despite aggressive antifungal therapy, the patient's neurological condition deteriorated, and he died on day 49. Autopsy confirmed extensive rhino-cerebral mucormycosis with angioinvasion, and Mucorales DNA was detected in brain tissue by quantitative PCR. To our knowledge, this represents the first reported case of R. miehei infection occurring within days after transplantation, preceding neutrophil engraftment. This case highlights the importance of recognizing mucormycosis even in the immediate post-transplant period and underscores the limitations of antifungal therapy in the absence of surgical debridement.
- 4 February 2026
- Published by Elsevier in Leukemia Research
- Vol. 162, 108183
Favorable outcomes with fludarabine, melphalan, and total-body irradiation 8–12Gy as an intensified conditioning regimen for adult allogeneic HCT
- 4 February 2026
- Published by Elsevier in Leukemia Research
- Vol. 162, 108183
Favorable outcomes with fludarabine, melphalan, and total-body irradiation 8–12Gy as an intensified conditioning regimen for adult allogeneic HCT
- Open Access
- 26 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 101
CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond.
- 26 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 101
Open AccessCXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond.
- Open Access
- 1 January 2025
- Published by The Japan Society for Hematopoietic Stem Cell Transplantation in Japanese Journal of Transplantation and Cellular Therapy
- Vol. 14 (1) , 1-5
Current status of diagnosis and treatment of late onset SOS
類洞閉塞症候群(SOS)は造血細胞移植後の主要な合併症の一つで,重症化すると致死的な経過を辿る。診断基準は修正Seattle基準とBaltimore基準が長年使用されてきた。2016年に欧州血液骨髄移植学会(EBMT)から新しい診断基準が提唱され,その後,2023年にその改訂版が公表された。本稿ではEBMT診断基準で提唱されたlate onset SOSについて現状と今後の課題を論じる。
- 1 January 2025
- Published by The Japan Society for Hematopoietic Stem Cell Transplantation in Japanese Journal of Transplantation and Cellular Therapy
- Vol. 14 (1) , 1-5
Open AccessCurrent status of diagnosis and treatment of late onset SOS
類洞閉塞症候群(SOS)は造血細胞移植後の主要な合併症の一つで,重症化すると致死的な経過を辿る。診断基準は修正Seattle基準とBaltimore基準が長年使用されてきた。2016年に欧州血液骨髄移植学会(EBMT)から新しい診断基準が提唱され,その後,2023年にその改訂版が公表された。本稿ではEBMT診断基準で提唱されたlate onset SOSについて現状と今後の課題を論じる。
- 18 January 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (2) , 205-209
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia
Acquired point mutations in the ABL1 gene are widely recognized as a cause of Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia (Ph+ B-ALL) that is resistant to tyrosine kinase inhibitors, whereas there are few reports about other types of the ABL1 mutation. Here, we report 2 cases of Ph+ B-ALL gaining a partial deletion type mutation of the ABL1 gene (Δ184-274 mutation), which resulted in truncation of the ABL1 molecule and loss of kinase activity. In both cases, the disease was refractory to multiple agents in the recurrent phase after allogeneic hematopoietic cell transplantation. This is a case report of a truncated ABL1 mutation in 2 patients with Ph+ B-ALL.
- 18 January 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (2) , 205-209
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia
Acquired point mutations in the ABL1 gene are widely recognized as a cause of Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia (Ph+ B-ALL) that is resistant to tyrosine kinase inhibitors, whereas there are few reports about other types of the ABL1 mutation. Here, we report 2 cases of Ph+ B-ALL gaining a partial deletion type mutation of the ABL1 gene (Δ184-274 mutation), which resulted in truncation of the ABL1 molecule and loss of kinase activity. In both cases, the disease was refractory to multiple agents in the recurrent phase after allogeneic hematopoietic cell transplantation. This is a case report of a truncated ABL1 mutation in 2 patients with Ph+ B-ALL.
- Open Access
- 23 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (4) , 585-594
Retrospective analyses of other iatrogenic immunodeficiency‐associated lymphoproliferative disorders in patients with rheumatic diseases
Summary: Other iatrogenic immunodeficiency‐associated lymphoproliferative disorders (OIIA‐LPDs) occur in patients receiving immunosuppressive drugs for autoimmune diseases; however, their clinicopathological and genetic features remain unknown. In the present study, we analysed 67 patients with OIIA‐LPDs, including 36 with diffuse large B‐cell lymphoma (DLBCL)‐type and 19 with Hodgkin lymphoma (HL)‐type. After discontinuation of immunosuppressive drugs, regression without relapse was achieved in 22 of 58 patients. Spontaneous regression was associated with Epstein–Barr virus positivity in DLBCL‐type (P = 0·013). The 2‐year overall survival and progression‐free survival (PFS) at a median follow‐up of 32·4 months were 92·7% and 72·1% respectively. Furthermore, a significant difference in the 2‐year PFS was seen between patients with DLBCL‐type and HL‐type OIIA‐LPDs (81·0% vs. 40·9% respectively, P = 0·021). In targeted sequencing of 47 genes in tumour‐derived DNA from 20 DLBCL‐type OIIA‐LPD samples, histone‐lysine N‐methyltransferase 2D (KMT2D; eight, 40%) and tumour necrosis factor receptor superfamily member 14 (TNFRSF14; six, 30%) were the most frequently mutated genes. TNF alpha‐induced protein 3 (TNFAIP3) mutations were present in four patients (20%) with DLBCL‐type OIIA‐LPD. Cases with DLBCL‐type OIIA‐LPD harbouring TNFAIP3 mutations had shorter PFS and required early initiation of first chemotherapy. There were no significant factors for spontaneous regression or response rates according to the presence of mutations. Overall, OIIA‐LPDs, especially DLBCL‐types, showed favourable prognoses.
- 23 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (4) , 585-594
Open AccessRetrospective analyses of other iatrogenic immunodeficiency‐associated lymphoproliferative disorders in patients with rheumatic diseases
Summary: Other iatrogenic immunodeficiency‐associated lymphoproliferative disorders (OIIA‐LPDs) occur in patients receiving immunosuppressive drugs for autoimmune diseases; however, their clinicopathological and genetic features remain unknown. In the present study, we analysed 67 patients with OIIA‐LPDs, including 36 with diffuse large B‐cell lymphoma (DLBCL)‐type and 19 with Hodgkin lymphoma (HL)‐type. After discontinuation of immunosuppressive drugs, regression without relapse was achieved in 22 of 58 patients. Spontaneous regression was associated with Epstein–Barr virus positivity in DLBCL‐type (P = 0·013). The 2‐year overall survival and progression‐free survival (PFS) at a median follow‐up of 32·4 months were 92·7% and 72·1% respectively. Furthermore, a significant difference in the 2‐year PFS was seen between patients with DLBCL‐type and HL‐type OIIA‐LPDs (81·0% vs. 40·9% respectively, P = 0·021). In targeted sequencing of 47 genes in tumour‐derived DNA from 20 DLBCL‐type OIIA‐LPD samples, histone‐lysine N‐methyltransferase 2D (KMT2D; eight, 40%) and tumour necrosis factor receptor superfamily member 14 (TNFRSF14; six, 30%) were the most frequently mutated genes. TNF alpha‐induced protein 3 (TNFAIP3) mutations were present in four patients (20%) with DLBCL‐type OIIA‐LPD. Cases with DLBCL‐type OIIA‐LPD harbouring TNFAIP3 mutations had shorter PFS and required early initiation of first chemotherapy. There were no significant factors for spontaneous regression or response rates according to the presence of mutations. Overall, OIIA‐LPDs, especially DLBCL‐types, showed favourable prognoses.